Home    Back

 149. Hemiconvulsion hemiplegia epilepsy syndrome
 [ 16 clinical trials,    22 drugs(DrugBank: 10 drugs),    6 target genes / 10 target pathways

Searched query = "Hemiconvulsion hemiplegia epilepsy syndrome", "One side convulsions", "Hemiplegia", "Epilepsy syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JapicCTI-19495801/10/20197 October 2019A pharmacokinetic, safety, and tolerability study of padsevonil in CYP2C19 genotyped healthy male Japanese study participants.An Open-Label, Parallel Group, Single-Center Study to Investigate the Pharmacokinetic, Safety, and Tolerability Profiles of Padsevonil in CYP2C19 Genotyped Healthy Male Japanese Study ParticipantsEpilepsy and epilepsy syndromeIntervention name : padsevonil
INN of the intervention : padsevonil
Dosage And administration of the intervention : Oral administration
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -
UCB Japan Co., Ltd.Recruiting2055Male39Phase 1Japan
2JPRN-JapicCTI-19463305/6/20197 October 2019A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study of T-817MA in Post-stroke Patients Undergoing Rehabilitation for Upper Limb HemiplegiaA Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study of T-817MA in Post-stroke Patients Undergoing Rehabilitation for Upper Limb HemiplegiaPatients with upper limb hemiplegia after cerebral infarction or cerebral hemorrhage (other than subarachnoid hemorrhage)Intervention name : T-817MA
INN of the intervention : Edonerpic
Dosage And administration of the intervention : Oral Multiple Dose
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -
FUJIFILM Toyama Chemical Co., LtdRecruiting2079BOTH45Phase 2Japan
3JPRN-jRCTs04219002022/04/201922 July 2019The Effectiveness of BEAR for hemiplegic patientsThe Effectiveness of Balance Exercise Assist Robot for convalescent patients with hemiplegia after stroke - EBEARCPHASStrokeUsing Balance Exercise Assist RobotEiichi SaitohRecruiting>=20 age old<90 age oldBoth60N/Anone
4NCT03860662February 26, 201918 March 2019Nociceptive Flexor Reflex and Antispastic TreatmensResearch Assistant DoctorStroke Sequelae;Spastic HemiplegiaDiagnostic Test: Nociceptor flexor reflex;Drug: Botox;Drug: BaclofenMustafa Kemal UniversityNot recruiting18 Years60 YearsAll30Phase 4Turkey
5JPRN-JapicCTI-18413704/1/20195 November 2019A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam as Replaement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age with Partial Seizures With or Without Secondary GeneralizationA Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam as Replaement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age with Partial Seizures With or Without Secondary GeneralizationEpilepsy and epilepsy syndromeIntervention name : brivaracetam
INN of the intervention : brivaracetam
Dosage And administration of the intervention : Intravenous (iv) injection
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -
UCB Japan Co., Ltd.Recruiting16BOTH10Phase 3Japan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6JPRN-JapicCTI-17361522/8/20175 November 2019A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam Subjects (>=16 to 80 Years of Age) With Partial Seizures With or Without Secondary GeneralizationA Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam Subjects (>=16 to 80 Years of Age) With Partial Seizures With or Without Secondary GeneralizationEpilepsy and epilepsy syndromeIntervention name : ucb 34714
INN of the intervention : Brivaracetam
Dosage And administration of the intervention : Oral administration
Control intervention name : Placebo
INN of the control intervention : -
Dosage And administration of the control intervention : -
UCB Japan Co., Ltd.Recruiting1680BOTH504Phase 3Japan, Asia except Japan
7JPRN-JapicCTI-17368705/8/20175 November 2019An Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary GeneralizationAn Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary GeneralizationEpilepsy and epilepsy syndromeIntervention name : brivaracetam
INN of the intervention : brivaracetam
Dosage And administration of the intervention : Oral administration
Control intervention name : Placebo
INN of the control intervention : -
Dosage And administration of the control intervention : -
UCB Japan Co., Ltd.Recruiting16BOTH124Phase 3Japan
8JPRN-JapicCTI-15310308/12/20155 November 2019A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EPILEPSYA DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EPILEPSYEpilepsy and epilepsy syndromeIntervention name : SPM927
INN of the intervention : Lacosamide
Dosage And administration of the intervention : oral administration
Control intervention name : Placebo
INN of the control intervention : -
Dosage And administration of the control intervention : -
UCB Japan Co., Ltd.Not Recruiting4BOTH242Phase 3Japan, Asia except Japan, North America, Europe, Oceania
9NCT02455232May 201516 December 2017Determine the Main Muscle Participant in the Deformation of the Elbow in Hemiplegic PatientsDetermine the Main Muscle Participant in the Deformation of the Elbow in Hemiplegic PatientsHemiplegiaProcedure: upper limb muscle block;Drug: 4cc of lidocaïne®Centre d'Investigation Clinique et Technologique 805Not recruiting18 Years75 YearsAll20N/AFrance
10NCT02408354March 201516 December 2017Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of ChildhoodEtude Pilote, Comparative, Monocentrique, randomisée, en Cross Over, en Double Aveugle, Contre Placebo, Testant l'efficacité de l'Huile triheptanoïne Dans Les Hémiplégies Alternantes de l'Enfant HEMIHEPAlternating Hemiplegia of ChildhoodDrug: Triheptanoin;Drug: PlaceboInstitut National de la Santé Et de la Recherche Médicale, FranceNot recruiting15 YearsN/AAll10Phase 2France
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11ChiCTR-ICR-150070222014-05-0118 April 2017A research of biomechanic stimulation and healing of hemiplegia gaitA research of biomechanic stimulation and healing of hemiplegia gaitstrokebotulinum toxin A type group:inject botulinum toxin A type;conventional treatment A group :conventional treatment;Dynamic electrical stimulation treatment group:Dynamic electrical stimulation;conventional treatment B group :conventional treatment;blank control group:null;validation group :botulinum toxin A type ;Nanjing Sports InstitudeRecruiting4070Bothbotulinum toxin A type group:30;conventional treatment A group :30;Dynamic electrical stimulation treatment group:30;conventional treatment B group :30;blank control group:30;validation group :30;New Treatment Measure Clinical StudyChina
12NCT01623622July 201216 December 2017Study of HC-58 in Upper Limb Hemiplegic Patients After StrokeA Phase 2 Study of HC-58 in Patients With Severe Upper Limb Hemiplegia After StrokeSevere Upper Limb HemiplegiaDrug: HC-58;Drug: PlaceboAsahi Kasei Pharma CorporationNot recruiting20 YearsN/AAll270Phase 2Japan
13EUCTR2009-015620-29-BE08/03/20107 October 2014The efficacy of the Botulinum toxin-A on the manual abilities in children with congenital spastic hemiplegia. Interest of the measure of the bimanual task performance.The efficacy of the Botulinum toxin-A on the manual abilities in children with congenital spastic hemiplegia. Interest of the measure of the bimanual task performance.The main objective of this study is to investigate the effect of Botulinum toxin A to improve the Upper Limb dysfunction in Hemiplegic Cerebral Palsy Children and in particular, its impact on Upper limb activity performance and how this might be translate in bimanual activities.
MedDRA version: 12.0 Level: LLT Classification code 10019475 Term: Hemiplegic infantile cerebral palsy
Trade Name: BOTOX
Product Name: BOTOX
Product Code: 9060X
Pharmaceutical Form: Injection*
CAS Number: 93384-43-1
Other descriptive name: BOTULINUM TOXIN TYPE A
Concentration unit: IU international unit(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Intramuscular use
AuthorisedFemale: yes
Male: yes
30Belgium
14NCT00931164August 200919 October 2017Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)Single-center Phase I/II Trial of Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO Trial)Alternating Hemiplegia of ChildhoodDrug: Sodium OxybateUniversity of UtahAlternating Hemiplegia of Childhood Foundation;Jazz PharmaceuticalsNot recruiting6 Months25 YearsAll6Phase 1/Phase 2United States
15NCT00632528March 200819 February 2015MEOPA to Improve Physical Therapy Results After Multilevel SurgeryEvaluation of the Efficacy of MEOPA Used to Obtain Better ROM Immediately After Multilevel Surgery in Children With Spastic Diplegia, Quadriplegia or Hemiplegia.Cerebral Palsy;Spastic Diplegia;Quadriplegia;HemiplegiaDrug: MEOPA;Drug: Medicinal airAssistance Publique - Hôpitaux de ParisNot recruiting6 Years20 YearsBoth64Phase 3France
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT00276185December 200519 February 2015HEMITOX : Effect of Botulinum Toxin Injections on Motor and Functional Ability of Upper Limb in Adults at Earlier Phases of Spastic Hemiplegia After StrokeEffect of Botulinum Toxin Injections on Motor and Functional Ability of Upper Limb in Adults at Earlier Phases of Spastic Hemiplegia After StrokeHemiplegiaDrug: Time delay treatment of botulinum toxinUniversity Hospital, Clermont-FerrandJ. Rebeyrol Hospital in Limoges;Rennes University Hospital;Center of Physical Medicine and Rehabilitation (Notre Dame de Lourdes Center in Rennes);Saint Jacques Hospital in Nantes;Centre Hospitalier Universitaire de Saint Etienne;Centre Régional de Département de médecine physique et réadaptation CHU-C3RF in Angers;Centre Hospitalier Universitaire de BesanconRecruiting18 YearsN/ABoth180Phase 3France

Back to top